Pim1 Serves as a Therapeutic Target for Inflammatory Arthritis via Mitochondrial Metabolism and Th17 Cell Differentiation - PubMed
4 hours ago
- #Pim1
- #inflammatory arthritis
- #Th17 cells
- Pim1 is identified as a therapeutic target for inflammatory arthritis, including rheumatoid arthritis (RA) and ankylosing spondylitis (AS).
- Pim1 expression is elevated in CD4+ T cells in patients with RA or AS and in mouse models of inflammatory arthritis.
- Conditional knockdown of Pim1 or using the Pim1 inhibitor AZD1208 alleviates inflammatory arthritis by reducing Th17 cell differentiation.
- Pim1 promotes Th17 cell differentiation by increasing mitochondrial calcium influx, activating oxidative phosphorylation.
- Nilotinib, an FDA-approved drug, is identified as a potential substitute for Pim1 inhibitors, showing efficacy in reducing Th17 cell differentiation and treating inflammatory arthritis in mouse models.